Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Weyerhaeuser Company Common Stock (WY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Weyerhaeuser Company Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.13 (market cap $6.57B), while Weyerhaeuser Company Common Stock trades at $19.16 (market cap $13.67B). The key difference: Weyerhaeuser Company Common Stock is far larger — about 2.1× Iovance Biotherapeutics Inc. Common Stock's market cap, and Weyerhaeuser Company Common Stock pays a 4.43% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IOVA | WY | |
|---|---|---|
Market Cap | $6.57B | $13.67B |
Volume | 11,838,721 | 6,820,453 |
Sector | Health | Real Estate |
52-Week High | $14.82 | $27.10 |
52-Week Low | $1.81 | $18.47 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $6.50B | $18.59B |
Dividend Yield | — | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
Weyerhaeuser (WY) trades at $18.97, up 0.16% with neutral technical signals. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while fundamentals reveal modest profitability with 6.89% net margin and 4.97% ROE. Recent news highlights institutional accumulation and upcoming Q3 earnings on October 29. The company maintains stable revenue at $6.9B but faces cash flow challenges with negative net cash flow of $203M in 2025.
Weyerhaeuser presents a mixed outlook with analyst consensus favoring bullish sentiment (52% buy ratings) and a $29.33 price target suggesting 55% upside. However, risks include weak dividend coverage, high leverage at 5x, and sensitivity to interest rates and housing market cycles. The stock's current proximity to 52-week lows offers potential value but requires careful monitoring of lumber demand recovery and Q3 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Weyerhaeuser Company Common Stock
Weyerhaeuser Company is a timberland-focused real estate investment trust (REIT) that owns and manages more than 10 million acres of timberland in US, in addition to timberlands under long-term license in Canada. The company also manufactures wood products, including lumber, oriented strand board, and engineered wood.
Read more on WY →
